186 related articles for article (PubMed ID: 38045061)
21. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
[TBL] [Abstract][Full Text] [Related]
22. Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors.
Ma YX; Liu FR; Zhang Y; Chen Q; Chen ZQ; Liu QW; Huang Y; Yang YP; Fang WF; Xi N; Kang N; Zhuang YL; Zhang Q; Jiang YZ; Zhang L; Zhao HY
Front Immunol; 2022; 13():1024755. PubMed ID: 36341335
[TBL] [Abstract][Full Text] [Related]
23. ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.
Tsukamoto S; Sugi NH; Nishibata K; Nakazawa Y; Ito D; Fukushima S; Nakagawa T; Ichikawa K; Kato Y; Kakiuchi D; Goto A; Itoh-Yagi M; Aota T; Inoue S; Yamane Y; Murai N; Azuma H; Nagao S; Sasai K; Akagi T; Imai T; Matsui J; Matsushima T
Mol Cancer Ther; 2023 Jan; 22(1):12-24. PubMed ID: 36279567
[TBL] [Abstract][Full Text] [Related]
24. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
[TBL] [Abstract][Full Text] [Related]
25. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
26. A novel human anti-AXL monoclonal antibody attenuates tumour cell migration.
Duan Y; Luo L; Qiao C; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Scand J Immunol; 2019 Aug; 90(2):e12777. PubMed ID: 31075180
[TBL] [Abstract][Full Text] [Related]
27. Gas6/Axl signaling pathway promotes proliferation, migration and invasion and inhibits apoptosis in A549 cells.
Wang D; Bi L; Ran J; Zhang L; Xiao N; Li X
Exp Ther Med; 2021 Nov; 22(5):1321. PubMed ID: 34630675
[TBL] [Abstract][Full Text] [Related]
28. A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Rios-Doria J; Favata M; Lasky K; Feldman P; Lo Y; Yang G; Stevens C; Wen X; Sehra S; Katiyar K; Liu K; Wynn R; Harris JJ; Ye M; Spitz S; Wang X; He C; Li YL; Yao W; Covington M; Scherle P; Koblish H
Front Oncol; 2020; 10():598477. PubMed ID: 33425754
[TBL] [Abstract][Full Text] [Related]
29. Immune Evasion Mechanism and AXL.
Son HY; Jeong HK
Front Oncol; 2021; 11():756225. PubMed ID: 34778071
[TBL] [Abstract][Full Text] [Related]
30. Engineered AXL
Duan Y; Hu B; Qiao C; Luo L; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Oncol Lett; 2019 Jun; 17(6):5784-5792. PubMed ID: 31186805
[TBL] [Abstract][Full Text] [Related]
31. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.
Moody G; Belmontes B; Masterman S; Wang W; King C; Murawsky C; Tsuruda T; Liu S; Radinsky R; Beltran PJ
Int J Cancer; 2016 Sep; 139(6):1340-9. PubMed ID: 27170265
[TBL] [Abstract][Full Text] [Related]
32. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
[TBL] [Abstract][Full Text] [Related]
34. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.
Hara T; Kimura A; Miyazaki T; Tanaka H; Morimoto M; Nakai K; Soeda J
Biochem Biophys Rep; 2020 Mar; 21():100726. PubMed ID: 32055714
[TBL] [Abstract][Full Text] [Related]
36. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Tanaka M; Siemann DW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32660000
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.
Kanlikilicer P; Ozpolat B; Aslan B; Bayraktar R; Gurbuz N; Rodriguez-Aguayo C; Bayraktar E; Denizli M; Gonzalez-Villasana V; Ivan C; Lokesh GLR; Amero P; Catuogno S; Haemmerle M; Wu SY; Mitra R; Gorenstein DG; Volk DE; de Franciscis V; Sood AK; Lopez-Berestein G
Mol Ther Nucleic Acids; 2017 Dec; 9():251-262. PubMed ID: 29246304
[TBL] [Abstract][Full Text] [Related]
38. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
Zammarchi F; Havenith KE; Chivers S; Hogg P; Bertelli F; Tyrer P; Janghra N; Reinert HW; Hartley JA; van Berkel PH
Mol Cancer Ther; 2022 Apr; 21(4):582-593. PubMed ID: 35086955
[TBL] [Abstract][Full Text] [Related]
39. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
40. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
